Implementation of nanoparticles in therapeutic radiation oncology
Source abstract
Abstract
Development and progress of cancer is a very complex disease process to comprehend because of the multiple changes in cellular physiology, pathology, and pathophysiology resulting from the numerous genetic changes from which cancer originates. As a result, most common treatments are not directed at the molecular level but rather at the tissue level. While personalized care is becoming an increasingly aim, the most common cancer treatments are restricted to chemotherapy, radiation, and surgery, each of which has a high likelihood of resulting in rather severe adverse side effects. For example, currently used radiation therapy does not discriminate between normal and cancerous cells and greatly relies on the external targeting of the radiation beams to specific cells and organs. Because of this, there is an immediate need for the development of new and innovative technologies that help to differentiate tumor cells and micrometastases from normal cells and facilitate the complete destruction of those cells. Recent advancements in nanoscience and nanotechnology have paved a way for the development of nanoparticles (NPs) as multifunctional carriers to deliver therapeutic radioisotopes for tumor targeted radiation therapy, to monitor their delivery, and improve the therapeutic index of radiation and tumor response to the treatment. The application of NPs in radiation therapy has aimed to improve outcomes in radiation therapy by increasing therapeutic effect in tumors and reducing toxicity on normal tissues. Because NPs possess unique properties, such as preferential accumulation in tumors and minimal uptake in normal tissues, it makes them ideal for the delivery of radiotherapy. This review provides an overview of the recent development of NPs for carrying and delivering therapeutic radioisotopes for systemic radiation treatment for a variety of cancers in radiation oncology.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Radiation Therapy and Dosimetry · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (72)
Show source-provided references
1. Abakumov MA, Shein SA, Vishvasrao H et al (2012) Visualization of experimental glioma C6 by MRI with magnetic nanoparticles conjugated with monoclonal antibodies to vascular endothelial growth factor. Bull Exp Biol Med 154:274–27710.1007/s10517-012-1929-8 ↗
2. Ahn KY, KoHK LBR et al (2014) Engineered protein nanoparticles for in vivo tumor detection. Biomaterials 35:6422–6429. doi: 10.1016/j.biomaterials.2014.04.04110.1016/j.biomaterials.2014.04.041 ↗
3. Alexiou C, Jurgons R, Schmid RJ et al (2003) Magnetic drug targeting—biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J Drug Target 11:139–14910.3109/1061186031000150791 ↗
4. Alexis F, Basto P, Levy-Nissenbaum E et al (2008) HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. Chem Med Chem 3:1839–184310.1002/cmdc.200800122 ↗
5. Allen BJ (2013) Systemic targeted alpha radiotherapy for cancer. J Biomed Phy Eng 3:67–80
6. Assaran DR, Shareghi B, Asoodeh A, Chamani J (2016) Multi-spectroscopic and molecular modeling studies of interaction between two different angiotensin I converting enzyme inhibitory peptide from gluten hydrolysate and human serum albumin. J Biomol Struct Dyn 26:1–1510.1080/07391102.2016.1264892 ↗
7. Baban DF, Seymour LW (1998) Control of tumour vascular permeability. Adv Drug Deliv Rev 34:109–11910.1016/S0169-409X(98)00003-9 ↗
8. Bae Y, Diezi TA, Zhao A, Kwon GS (2007) Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J Control Release 122:324–33010.1016/j.jconrel.2007.05.038 ↗
9. Ballangrud AM, Yang WH, Charlton DE et al (2001) Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 61:2008–2014
10. Bellocq NC, Pun SH, Jensen GS, Davis ME (2003) Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14:1122–113210.1021/bc034125f ↗
11. Betancourt T, Brown B, Brannon-Peppas L (2007) Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine (Lond) 2:219–23210.2217/17435889.2.2.219 ↗
12. Cai W, Gao T, Hong H, Sun J (2008) Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol, Sci Applications 1:17–3210.2147/NSA.S3788 ↗
13. Cherukuri P, Glazer ES, Curley SA (2010) Targeted hyperthermia using metal nanoparticles. Adv Drug Deliv Rev 62:339–34510.1016/j.addr.2009.11.006 ↗
14. Chidambaram M, Manavalan R, Kathiresan K (2011) Nanotherapeutics to overcome conventional cancer chemotherapy limitations. J Pharm Pharm Sci 14:67–7710.18433/J30C7D ↗
15. Cho CF, Shukla S, Simpson EJ (2014) Molecular targeted viral nanoparticles as tools for imaging cancer. Methods in Molecular Biology (Clifton, NJ) 1108. NIH Public Access:211–230. doi: 10.1007/978-1-62703-751-8_1610.1007/978-1-62703-751-8_16 ↗
16. Curnis F, Fiocchi M, Sacchi A (2016) NGR-tagged nano-gold: a new CD13-selective carrier for cytokine delivery to tumors. Nano Res 9:1393–1408. doi: 10.1007/s12274-016-1035-810.1007/s12274-016-1035-8 ↗
17. Danhier F, Feron O, Preat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135–14610.1016/j.jconrel.2010.08.027 ↗
18. Dicheva BM, ten Hagen TL, Schipper D (2014) Targeted and heat triggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes. J Control Release 195:37–48. doi: 10.1016/j.jconrel.2014.07.05810.1016/j.jconrel.2014.07.058 ↗
19. Dong X, Mumper RJ (2010) Nanomedicine strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 5:597–61510.2217/nnm.10.35 ↗
20. Flenniken ML, Liepold LO, Crowley BE et al (2005) Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun (Camb) 4:447–44910.1039/b413435d ↗
21. Hatakeyama H, Akita H, Ishida E et al (2007) Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm 324:194–20010.1016/j.ijpharm.2007.04.037 ↗
22. Hughes AD, King MR (2012) Nanobiotechnology for the capture and manipulation of circulating tumor cells. Wiley Interdiscip Rev Nanomed Nanobiotechnol 4:291–309. doi: 10.1002/wnan.16810.1002/wnan.168 ↗
23. Humm JL (1987) A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 13:1767–177310.1016/0360-3016(87)90176-3 ↗
24. Iinuma H, Maruyama K, Okinaga K et al (2002) Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99:130–13710.1002/ijc.10242 ↗
25. Iranfar H, Rajabi O, Salari R, Chamani J (2012) Probing the interaction of human serum albumin with ciprofloxacin in the presence of silver nanoparticles of three sizes: multispectroscopic and ζ potential investigation. J Phys Chem B 116(6):1951–196410.1021/jp210685q ↗
26. Iyer AK, Singh A, Ganta S, Amiji MM (2013) Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 65:1784–1802. doi: 10.1016/j.addr.2013.07.01210.1016/j.addr.2013.07.012 ↗
27. Jones A, Harris AL (1998) New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer J Sci Am 4:209–217
28. Kam NW, O'Connell M, Wisdom JA, Dai H (2005) Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc Natl Acad Sci U S A 102:11600–1160510.1073/pnas.0502680102 ↗
29. Kamaly N, Xiao Z, Valencia PM, Radovic-Moreno AF, Farokhzad OC (2012) Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 41:2971–3010. doi: 10.1039/c2cs15344k10.1039/c2cs15344k ↗
30. Kassis AI (2008) Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med 38:358–366. doi: 10.1053/j.semnuclmed.2008.05.00210.1053/j.semnuclmed.2008.05.002 ↗
31. Kim YS, Brechbiel MW (2012) An overview of targeted alpha therapy. Tumour Biol 33:573–59010.1007/s13277-011-0286-y ↗
32. Kobayashi T, Ishida T, Okada Y et al (2007) Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug-resistant tumor cells. Int J Pharm 329:94–10210.1016/j.ijpharm.2006.08.039 ↗
33. Kontermann RE (2006) Immunoliposomes for cancer therapy. Curr Opin Mol Ther 8:39–45
34. Kratochwil C, Giesel FL, Bruchertseifer F et al (2014) 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumors refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imag 41:2106–2119. doi: 10.1007/s00259-014-2857-910.1007/s00259-014-2857-9 ↗
35. Kukowska-Latallo JF, Candido KA, Cao Z et al (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65:5317–532410.1158/0008-5472.CAN-04-3921 ↗
36. Kunjachan S, Pola R, Gremse F et al (2014) Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett 14:972–981. doi: 10.1021/nl404391r10.1021/nl404391r ↗
37. Kunstfeld R, Wickenhauser G, Michaelis U et al (2003) Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a “humanized” SCID mouse model. J Invest Dermatol 120:476–48210.1046/j.1523-1747.2003.12057.x ↗
38. Kwatra D, Venugopal A, Anant S (2013) Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer. Translational Cancer Res 2:330–342. doi: 10.21037/155010.21037/1550 ↗
39. Letfullin RR, Iversen CB, George TF (2011) Modeling nano photothermal therapy: kinetics of thermal ablation of healthy and cancerous cell organelles and gold nanoparticles. Nanomedicine 7:137–14510.1016/j.nano.2010.06.011 ↗
40. Li L, Wartchow CA, Danthi SN et al (2004) A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 58:1215–122710.1016/j.ijrobp.2003.10.057 ↗
41. Li J, Zheng L, Cai H et al (2013) Polyethyleneimine-mediated synthesis of folic acid-targeted iron oxide nanoparticles for in vivo tumor MR imaging. Biomaterials 34:8382–839210.1016/j.biomaterials.2013.07.070 ↗
42. Li Y, Liu Q, Li W et al (2016) Design and validation of PEG-derivatized vitamin E copolymer for drug delivery into breast cancer. Bioconjug Chem 27:1889–1899. doi: 10.1021/acs.bioconjchem.6b0029210.1021/acs.bioconjchem.6b00292 ↗
43. Lowery AR, Gobin AM, Day ES, Halas NJ, West JL (2006) Immunonanoshells for targeted photothermal ablation of tumor cells. Int J Nanomedicine 1:149–15410.2147/nano.2006.1.2.149 ↗
44. Mitra A, Nan A, Line BR, Ghandehari H (2006) Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 12:4729–474910.2174/138161206779026317 ↗
45. Mody VV, Siwale R, Singh A, Mody HR (2010) Introduction to metallic nanoparticles. J Pharm Bioallied Sci 2:282–28910.4103/0975-7406.72127 ↗
46. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L (2006) Nanoparticle imaging of integrins on tumor cells. Neoplasia 8:214–22210.1593/neo.05769 ↗
47. Moroz P, Jones S, Gray B (2003) Magnetically mediated hyperthermia: current status and future directions. Int J Hyperth 8:267–284
48. Muddineti OS, Ghosh B, Biswas S (2015) Current trends in using polymer coated gold nanoparticles for cancer therapy. Int J Pharm 484:252–267. doi: 10.1016/j.ijpharm.2015.02.03810.1016/j.ijpharm.2015.02.038 ↗
49. Mulford DA, Scheinberg DA, Jurcic JG (2005) The promise of targeted {alpha}-particle therapy. J Nucl Med 46(Suppl 1):199S–204S
50. Nakagawa T, Gonda K, Kamei T et al (2016) X-ray computed tomography imaging of a tumor with high sensitivity using gold nanoparticles conjugated to a cancer-specific antibody via polyethylene glycol chains on their surface. Sci Technol Adv Mater 17:387–397. doi: 10.1080/14686996.2016.119416710.1080/14686996.2016.1194167 ↗
51. Pan L, Liu J, He Q, Wang L, Shi J (2013) Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials 34:2719–2730. doi: 10.1016/j.biomaterials.2012.12.04010.1016/j.biomaterials.2012.12.040 ↗
52. Paquet F, Barbey P, Bardies M et al (2013) The assessment and management of risks associated with exposures to short-range auger- and beta-emitting radionuclides. State of the art and proposals for lines of research J Radiol Prot 33:R1–16. doi: 10.1088/0952-4746/33/1/R110.1088/0952-4746/33/1/R1 ↗
53. Perche F, Torchilin VP (2013) Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Delivery 2013:1–32. doi: 10.1155/2013/70526510.1155/2013/705265 ↗
54. Puri A, Kramer-Marek G, Campbell-Massa R et al (2008) HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res 18:293–30710.1080/08982100802457377 ↗
55. Ranganathan R, Madanmohan S, Kesavan A et al (2012) Nanomedicine: towards the development of patient-friendly drug-delivery systems for oncological applications. Int J Nanomedicine 7:1043–1060
56. Rosenblat TL, McDevitt MR, Mulford DA et al (2010) Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 16:5303–531110.1158/1078-0432.CCR-10-0382 ↗
57. Rossin R, Pan D, Qi K et al (2005) 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J Nucl Med 46:1210–1218
58. Schipper ML, Riese CG, Seitz S et al (2007) Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo. Eur J Nucl Med Mol Imaging 34:638–65010.1007/s00259-006-0254-8 ↗
59. Shenoy D, Little S, Langer R, Amiji M (2005) Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs. 1. In vitro evaluations. Mol Pharm 2:357–36610.1021/mp0500420 ↗
60. Shukla R, Chanda N, Zambre A et al (2012) Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci U S A 109:12426–1243110.1073/pnas.1121174109 ↗
61. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2015. CA Cancer J Clin 66:7–30. doi: 10.3322/caac.2133210.3322/caac.21332 ↗
62. Sofou S (2008) Radionuclide carriers for targeting of cancer. Int J Nanomedicine 3:181–19910.2147/IJN.S2736 ↗
63. Sung W, Jung S, Ye SJ (2016) Evaluation of the microscopic dose enhancement for nanoparticle-enhanced auger therapy. Phy Med Biol 61:7522–7535. doi: 10.1088/0031-9155/61/21/752210.1088/0031-9155/61/21/7522 ↗
64. Sutton D, Nasongkla N, Blanco E, Gao J (2007) Functionalized micellar systems for cancer targeted drug delivery. Pharm Res 24:1029–104610.1007/s11095-006-9223-y ↗
65. Tang QS, Zhang DS, Cong XM, Wan ML, Jin LQ (2008) Using thermal energy produced by irradiation of Mn-Zn ferrite magnetic nanoparticles (MZF-NPs) for heat-inducible gene expression. Biomaterials 29:2673–267910.1016/j.biomaterials.2008.01.038 ↗
66. Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–145810.1016/S1359-6446(05)03575-0 ↗
67. Wadas TJ, Pandya DN, Solingapuram Sai KK, Mintz A (2014) Molecular targeted α-particle therapy for oncologic applications. AJR AmJ Roentgenol 203:253–260. doi: 10.2214/AJR.14.1255410.2214/AJR.14.12554 ↗
68. Wang C, Bao C, Liang S et al (2014) HAI-178 antibody-conjugated fluorescent magnetic nanoparticles for targeted imaging and simultaneous therapy of gastric cancer. Nanoscale Res Lett 9:274–283. doi: 10.1186/1556-276X-9-27410.1186/1556-276X-9-274 ↗
69. Yu J, Chu X, Hou Y (2014) Stimuli-responsive cancer therapy based on nanoparticles. Chem Commun 50:11614–11630. doi: 10.1039/C4CC03984J10.1039/C4CC03984J ↗
70. Zhang L, Yu F, Cole AJ et al (2009) Gum arabic-coated magnetic nanoparticles for potential application in simultaneous magnetic targeting and tumor imaging. AAPS J 11:693–69910.1208/s12248-009-9151-y ↗
71. Zhang L, Chen H, Wang L et al (2010) Delivery of therapeutic radioisotopes using nanoparticle platforms: potential benefit in systemic radiation therapy. Nanotechnol, Sci Applications 3:159–170
72. Ziyarat FP, Asoodeh A, Barfesh ZS et al (2014) Probing the interaction of lysozeme with ciprofloxacine in the presence of different-sized Ag nano-particles by multispectroscopic techniques and isothermal titration calorimetry. J Biomol Struct Dyn 32:613–62910.1080/07391102.2013.785919 ↗